FDA product code PGH: Hsv-1 And Hsv-2 Cns Nucleic-Acid Based Panel
PGH is the FDA product code for hsv-1 and hsv-2 cns nucleic-acid based panel. It is a Class II device, regulated under 21 CFR 866.3307 and reviewed by the Microbiology panel. FDA has cleared 2 510(k) submissions under PGH, 1 in the last five years, from 2 different applicants. The average 510(k) review took 146 days (median 146); 263 days on average over the last three years. 1 De Novo request was granted under it. FDA has posted 1 recall for PGH devices.
Definition
Intended for the qualitative detection and differentiation of HSV-1 and HSV-2 in cerebrospinal fluid (CSF) from patients with signs and symptoms of Herpes Simplex Virus (HSV) central nervous system (CNS) infection. This test is an aid in the diagnosis of HSV-1 and HSV-2 CNS infections in conjunction with other clinical and laboratory findings. Negative results do not preclude HSV-1 or HSV-2 infection and should not be used as the sole basis for treatment or other patient management decisions.
Classification
| Field | Value |
|---|---|
| Device name | Hsv-1 And Hsv-2 Cns Nucleic-Acid Based Panel |
| Device class | Class II |
| Regulation | 21 CFR 866.3307 |
| Review panel | MI — Microbiology |
| Medical specialty | Microbiology |
| Premarket route | 510(k) |
| Life-sustaining or supporting | Yes |
510(k) clearances per year for PGH
| Year | Clearances | Avg. review days |
|---|---|---|
| 2025 | 1 | 263 |
Compare with all 510(k) review times · Search every PGH clearance
Top PGH applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Midiagnostics NV | 1 | 2025-09-30 |
| Focus Diagnostics | 1 | 2014-07-01 |
Most recent PGH clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K250050 | Midiagnostics NV | miDiagnostics HSV-1&2 CSF Test | 2025-09-30 | 263 |
| K141458 | Focus Diagnostics | SIMPLEXA HSV 1&2 DIRECT/POSITIVE CONTROL PACK | 2014-07-01 | 29 |
Recalls for PGH devices
1 product recalls in 1 recall events; 0 initiated in the last five years and 0 still open. Most recent: 2016-02-10.
Frequently asked questions
What is FDA product code PGH?
PGH is the FDA product code for hsv-1 and hsv-2 cns nucleic-acid based panel. It is a Class II device, regulated under 21 CFR 866.3307 and reviewed by the Microbiology panel.
What device class is PGH?
Class II, regulation 21 CFR 866.3307. Typical premarket route: 510(k).
How long does a 510(k) take for product code PGH?
Across 2 cleared submissions the average was 146 days from receipt to decision (median 146).
Which companies have the most PGH clearances?
Midiagnostics NV (1); Focus Diagnostics (1).
Have PGH devices been recalled?
Yes: 1 product recalls across 1 recall events; the most recent began 2016-02-10.
Next steps
- Run an FDA pathway report with predicate devices for product code PGH
- Run a recall and safety report across every PGH manufacturer
- Watch product code PGH for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Microbiology product codes · FDA product code lookup · 510(k) database search · 510(k) review times